XML 74 R54.htm IDEA: XBRL DOCUMENT
v3.21.2

Commitments and Contingencies (Details) | Aug. 04, 2021 USD ($) item | Sep. 30, 2021 USD ($)
--- | --- | ---
Loss Contingencies [Line Items] |  |
Number Of Business Days | 2 |
Zealand Pharma |  |
Loss Contingencies [Line Items] |  |
Loss contingency accrual |  | $ 0
Zealand Pharma | Arbitration Resolution Agreement |  |
Loss Contingencies [Line Items] |  |
Additional milestone payment | $ 1,500,000 |
Litigation Settlement, Collaborative Arrangement Milestone Payment Reduction Percentage | 50.00% |
Percentage of reduction in royalty payable | 50.00% |
Percentage of sales milestone reductions | 50.00% |
Future development milestone payable | $ 2,750,000 |
Registration proposal payable | 1,000,000.0 |
Commercial launch expenses | $ 1,750,000 |
Number of geographic territories | item | 3 |
Zealand Pharma | Arbitration Resolution Agreement | Phase 2 clinical trial |  |
Loss Contingencies [Line Items] |  |
Milestone payment | $ 1,000,000.0 |
Zealand Pharma | Arbitration Resolution Agreement | Phase 3 clinical trial |  |
Loss Contingencies [Line Items] |  |
Milestone payment | $ 1,500,000 |

X
- Definition The amount of future development milestone including commercial launch expenses for launch in the three geographic territories payable under the collaboration agreement. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementCommercialLaunchExpensesPayable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of future development milestone payable under the collaboration agreement. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementFutureDevelopmentMilestonePayable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of future development milestone including registration proposal payable under the collaboration agreement. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementRegistrationProposalExpensesPayable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the percentage of sales milestone reductions resulting from dispute resolution agreement. + References No definition available. + Details
Name: | ptgx_LitigationSettlementCollaborativeArrangementMilestonePaymentReductionPercentage
Namespace Prefix: | ptgx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of sales milestone reductions resulting from dispute resolution agreement. + References No definition available. + Details
Name: | ptgx_LitigationSettlementCollaborativeArrangementSalesMilestonePaymentReductionPercentage
Namespace Prefix: | ptgx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Business Days. + References No definition available. + Details
Name: | ptgx_NumberOfBusinessDays
Namespace Prefix: | ptgx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of geographic territories. + References No definition available. + Details
Name: | ptgx_NumberOfGeographicTerritories
Namespace Prefix: | ptgx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Collaboration Agreement Development Additional Milestone Payable. + References No definition available. + Details
Name: | ptgx_ResearchAndCollaborationAgreementDevelopmentAdditionalMilestonePayable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of development milestone payable under the research and collaboration agreement. + References No definition available. + Details
Name: | ptgx_ResearchAndCollaborationAgreementDevelopmentMilestonePayable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of reduction in royalty payable. + References No definition available. + Details
Name: | ptgx_RoyaltiesOnNetProductSalesPercentagesReduction
Namespace Prefix: | ptgx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=ptgx_ArbitrationResolutionAgreementWithZealandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_PhaseTwoClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_PhaseThreeClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |